T-DXd in Early-Stage HER2+ Breast Cancer?

T-DXd in Adjuvant and Neoadjuvant Seeing in Early-Stage HER2+ Breast Cancer? Replacement for Classical Chemotherapy?

In this CHM Conversations clip, Dr. Paolo Tarantino and Dr. Jason Mouabbi explore the potential of trastuzumab deruxtecan (T-DXd) in non-metastatic HER2-positive breast cancer. They break down the DESTINY-Breast05 and DESTINY-Breast11 trials, discussing trial design, the shift away from traditional chemotherapy both in the neoadjuvant as well as the adjuvant setting with residual disease, and the hope for the next generation of drugs to prevent recurrence and metastasis in the first place, raising the possibility of curing the patient.

They also highlight the importance of managing interstitial lung disease (ILD), a known risk of T-DXd, especially notate the Five S’s, i.e. Screen, Scan, Synergy, Suspend & Steroids, with particular emphasis on early diagnosis and treatment.